James William Rogers Sells 26,313 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 26,313 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the sale, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. This represents a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Tuesday, August 18th, James William Rogers sold 22,529 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $1,117,663.69.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00.

Tempus AI Stock Performance

Shares of TEM traded up $5.40 on Thursday, reaching $66.65. The company’s stock had a trading volume of 20,103,049 shares, compared to its average volume of 5,600,288. The stock’s 50 day simple moving average is $52.44 and its two-hundred day simple moving average is $51.21. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock has a market capitalization of $12.03 billion, a P/E ratio of -46.28 and a beta of 3.58. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the prior year, the company earned ($0.22) earnings per share. The firm’s revenue was up 21.6% on a year-over-year basis. Research analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after acquiring an additional 817,014 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after purchasing an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in Tempus AI during the 4th quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its stake in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. raised its stake in Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the period. 24.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of recent research reports. Lake Street Capital downgraded Tempus AI to a “hold” rating in a research note on Monday, July 20th. Piper Sandler decreased their target price on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 4th. Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Wolfe Research started coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $65.69.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.